Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

Investor Overview

Investor Overview

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

News Releases

Date Title and Summary Additional Formats
Toggle Summary Charles River Laboratories Announces First-Quarter 2020 Results
– First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $1.84 – – Revises 2020 Guidance Due to COVID-19 Impact – WILMINGTON, Mass. --(BUSINESS WIRE)--May 7, 2020-- Charles River Laboratories International, Inc.
View HTML
Toggle Summary Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call
WILMINGTON, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7 th ,
View HTML
Toggle Summary Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)--Mar. 30, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex , a leader in preclinical digital pathology software-as-a-service.
View HTML
Toggle Summary Charles River Laboratories To Participate In Barclays Global Healthcare Conference
WILMINGTON, Mass. --(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will participate in the Barclays Global Healthcare Conference . The Company will present on Wednesday, March 11 th , at 10:15 a.m. ET .
View HTML
Upcoming Events
There are currently no events scheduled.

Featured Report

2019 Annual Report (PDF)